June 14, 2024

228-OR: Effect of Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, on Cardioinflammatory Lipids

Key Points

Key points are not available for this paper at this time.

Abstract

Introduction Altimmune Inc. B. Georges: Employee; Altimmune. M.S. Roberts: Employee; Altimmune Inc. M. Harris: Employee; Altimmune Inc. S.K. Browne: Employee; Altimmune Inc.

Bookmark

Cite This Study

Suschak et al. (Fri,) studied this question.

synapsesocial.com/papers/68e64c55b6db6435875dd72a https://doi.org/https://doi.org/10.2337/db24-228-or

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study2024 · 135 citations
2262-OR: Pemvidutide, a GLP-1/Glucagon Dual Receptor Agonist, in Subjects with Overweight or Obesity—A 48-Week, Placebo-Controlled, Phase 2 (MOMENTUM) Trial2024 · 14 citations
31662-P: Petrelintide (ZP8396) Significantly Reduces Fat Mass while Preserving Lean Mass in DIO Rats2024
4121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study2024
5116-OR: GL0034 (Utreglutide), a Novel GLP-1RA, Increases Liver FGF-21 and Demonstrates Significant Efficacy on Weight Loss, HbA1c, and Triglycerides in db/db Mice2024

Bookmark